• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Liver Biopsy Market Trends

    ID: MRFR/MED/4087-HCR
    110 Pages
    Kinjoll Dey
    October 2025

    Liver Biopsy Market Research Report Information By Type (Percutaneous, Transjugular, Laparoscopic), Indication (Nonalcoholic Fatty Liver Disease, Chronic Hepatitis B Or C), End User (Hospitals & Clinics, Diagnostic Centers)-Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Liver Biopsy Market Infographic
    Purchase Options

    Market Trends

    Key Emerging Trends in the Liver Biopsy Market

    The liver biopsy market is seeing huge patterns and changes as it assumes a significant part in diagnosing different liver circumstances, including liver cirrhosis, hepatitis, and fatty liver disease. This market is driven by the rising pervasiveness of liver problems overall and the requirement for exact indicative systems. With the worldwide rise in liver diseases, there is a developing interest for exact demonstrative apparatuses. Liver biopsies are viewed as a highest quality level for plotting liver conditions, prompting an expanded reception of biopsy techniques. The market is affected by the predominance of variables like liquor utilization, viral contaminations, and non-alcoholic fatty liver disease (NAFLD). The market is encountering a shift towards non-invasive alternatives to conventional liver biopsy methodology. Innovations, for example, elastography and imaging modalities like FibroScan are acquiring fame as they offer symptomatic pieces of knowledge without the invasiveness related with customary biopsy strategies. This pattern mirrors a more extensive development in medical care towards patient-accommodating demonstrative choices. The rise of precision medication has affected the liver biopsy market, prompting more customized and designated approaches in diagnosing and treating liver issues. Sub-atomic diagnostics and hereditary testing are becoming essential pieces of liver biopsy systems, considering a superior comprehension of individual patient profiles and empowering custom-made treatment methodologies. Early discovery of liver diseases is basic for successful treatment. The market is seeing a developing accentuation on the significance of early finding, provoking medical care suppliers and patients to select liver biopsy as a solid strategy for recognizing liver circumstances in their beginning phases. This proactive methodology adds to worked on quiet results. Minimally invasive liver biopsy techniques are building up forward momentum, offering patients a not so much invasive but rather more agreeable experience. Strategies, for example, laparoscopic or percutaneous liver biopsy are becoming standard practices in numerous medical care settings. The market is answering the interest for methods that limit patient inconvenience and recuperation time.

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    What is the expected growth rate of the global liver biopsy market?

    Liver biopsy market size is projected to expand at 6.92% CAGR from 2024-2032.

    What factors can drive the global liver biopsy market?

    Liver biopsy market is driven by large prevalence of liver diseases and a rise of biopsy tests undertaken for its diagnosis.

    What factors can restrain the global liver biopsy market growth?

    High costs of diagnostic devices can stunt the global liver biopsy market growth.

    Name the key players of the global liver biopsy market?

    Fujifilm Medical Systems, Leica Biosystems, Medtronic, RI.MOS., INRAD Inc., Intact Medical Corp., Cook Medical, Hologic, Inc., Mauna Kea Technologies, Veran medical, Sterylab, Argon Medical Devices, Inc., Becton, Dickinson and Company, C. R. Bard, Inc., Boston Scientific Corporation, and MDxHealth are key players of the global liver biopsy market.

    Market Summary

    As per MRFR analysis, the Liver Biopsy Market Size was estimated at 0.92 USD Billion in 2024. The Liver Biopsy industry is projected to grow from 0.9891 in 2025 to 2.04 by 2035, exhibiting a compound annual growth rate (CAGR) of 7.51 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Liver Biopsy Market is experiencing a transformative shift towards minimally invasive techniques and advanced imaging integration.

    • Minimally invasive techniques are gaining traction, enhancing patient comfort and recovery times.
    • The integration of imaging technologies is improving the accuracy and efficiency of liver biopsies.
    • North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector.
    • The increasing prevalence of liver diseases and rising demand for personalized medicine are driving market growth.

    Market Size & Forecast

    2024 Market Size 0.92 (USD Billion)
    2035 Market Size 2.04 (USD Billion)
    CAGR (2025 - 2035) 7.51%
    Largest Regional Market Share in 2024 Americas

    Major Players

    <p>F. Hoffmann-La Roche Ltd (CH), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (DE), Becton, Dickinson and Company (US), Medtronic plc (IE), Hologic, Inc. (US), PerkinElmer, Inc. (US)</p>

    Market Trends

    The Liver Biopsy Market is currently experiencing a transformation driven by advancements in technology and an increasing prevalence of liver diseases. As healthcare systems evolve, there is a growing emphasis on minimally invasive procedures, which are perceived to enhance patient comfort and reduce recovery times. This shift is likely to influence the demand for liver biopsy techniques, as practitioners seek to adopt methods that align with contemporary medical practices. Furthermore, the integration of imaging technologies into biopsy procedures appears to improve diagnostic accuracy, thereby fostering greater confidence among healthcare providers and patients alike. In addition to technological advancements, the Liver Biopsy Market is also shaped by the rising awareness of liver health and the importance of early diagnosis. Educational initiatives and public health campaigns are likely to contribute to an increase in screening and diagnostic procedures, which may further drive market growth. As the global population ages, the incidence of liver-related conditions is expected to rise, necessitating more effective diagnostic tools. Overall, the Liver Biopsy Market seems poised for growth, with innovations and heightened awareness playing pivotal roles in its evolution.

    Minimally Invasive Techniques

    The trend towards minimally invasive liver biopsy techniques is gaining traction, as these methods are associated with reduced patient discomfort and quicker recovery times. This shift reflects a broader movement within the healthcare sector towards procedures that prioritize patient well-being while maintaining diagnostic efficacy.

    Integration of Imaging Technologies

    The incorporation of advanced imaging technologies into liver biopsy procedures is becoming increasingly prevalent. Techniques such as ultrasound and MRI guidance are enhancing the precision of biopsies, which may lead to improved diagnostic outcomes and greater acceptance among healthcare professionals.

    Rising Awareness of Liver Health

    There is a noticeable increase in public awareness regarding liver health, driven by educational campaigns and advocacy efforts. This heightened awareness is likely to result in more individuals seeking diagnostic evaluations, thereby expanding the market for liver biopsy procedures.

    The increasing prevalence of liver diseases and advancements in biopsy techniques are driving a notable evolution in the global liver biopsy market, reflecting a growing emphasis on precision medicine and patient-centered care.

    U.S. National Library of Medicine

    Liver Biopsy Market Market Drivers

    Increasing Prevalence of Liver Diseases

    The rising incidence of liver diseases, including hepatitis and cirrhosis, is a primary driver of the Liver Biopsy Market. According to recent data, liver diseases affect millions worldwide, leading to a heightened demand for diagnostic procedures. This trend is particularly evident in regions with high rates of viral hepatitis, where liver biopsies are essential for assessing disease progression. The need for accurate diagnosis and monitoring of liver conditions propels the market forward, as healthcare providers seek reliable methods to evaluate liver health. Furthermore, the increasing burden of non-alcoholic fatty liver disease (NAFLD) is contributing to the demand for liver biopsies, as clinicians require precise information to guide treatment decisions. As awareness of liver health continues to grow, the Liver Biopsy Market is likely to expand to meet the needs of patients and healthcare systems.

    Rising Demand for Personalized Medicine

    The shift towards personalized medicine is emerging as a significant driver in the Liver Biopsy Market. As healthcare moves away from a one-size-fits-all approach, the need for tailored treatment plans based on individual patient profiles becomes increasingly important. Liver biopsies play a crucial role in this paradigm shift, providing essential information about liver pathology that informs personalized treatment strategies. The ability to assess liver tissue at a molecular level allows clinicians to make more informed decisions regarding therapy options, particularly in the context of liver cancer and chronic liver diseases. This trend is likely to enhance the demand for liver biopsies, as healthcare providers seek to optimize patient outcomes through individualized care. Consequently, the Liver Biopsy Market is poised for growth as the focus on personalized medicine continues to gain traction.

    Regulatory Support for Diagnostic Procedures

    Regulatory support for diagnostic procedures is an essential factor driving the Liver Biopsy Market. Governments and health organizations are increasingly recognizing the importance of accurate diagnostic tools in managing liver diseases. This recognition has led to the establishment of guidelines and frameworks that promote the use of liver biopsies as a standard practice in clinical settings. Additionally, regulatory bodies are working to streamline the approval processes for new biopsy technologies, encouraging innovation and adoption within the market. As a result, healthcare providers are more likely to incorporate liver biopsy procedures into their diagnostic protocols, thereby increasing demand. The ongoing support from regulatory agencies is expected to foster a favorable environment for the Liver Biopsy Market, ultimately enhancing patient outcomes through improved diagnostic accuracy.

    Growing Investment in Healthcare Infrastructure

    Investment in healthcare infrastructure is a vital driver of the Liver Biopsy Market. As countries prioritize the enhancement of healthcare systems, the availability of advanced diagnostic tools, including liver biopsy procedures, is expected to increase. This trend is particularly pronounced in emerging economies, where governments and private sectors are collaborating to improve healthcare access and quality. The establishment of specialized liver clinics and diagnostic centers is likely to facilitate the adoption of liver biopsy techniques, thereby expanding the market. Furthermore, increased funding for research and development in liver disease diagnostics is anticipated to lead to innovative solutions that enhance the efficacy of liver biopsies. As healthcare infrastructure continues to evolve, the Liver Biopsy Market is expected to benefit from improved access to diagnostic services and enhanced patient care.

    Technological Advancements in Biopsy Techniques

    Technological innovations in biopsy techniques are significantly influencing the Liver Biopsy Market. The development of minimally invasive procedures, such as ultrasound-guided liver biopsies, has improved patient outcomes and reduced complications. These advancements not only enhance the accuracy of liver disease diagnosis but also increase patient comfort, leading to higher acceptance rates of biopsy procedures. Moreover, the integration of imaging technologies, such as MRI and CT scans, with biopsy techniques allows for more precise targeting of liver lesions. This synergy between technology and clinical practice is expected to drive market growth, as healthcare providers adopt these advanced methods to improve diagnostic accuracy. As the industry continues to evolve, the introduction of new technologies may further transform the landscape of liver biopsies, making them safer and more effective.

    Market Segment Insights

    By Type: Percutaneous Biopsy (Largest) vs. Laparoscopic Biopsy (Fastest-Growing)

    <p>In the Liver Biopsy Market, the percutaneous biopsy segment dominates in terms of market share, primarily due to its minimally invasive nature and widespread acceptance among healthcare professionals. This method accounts for a significant portion of liver biopsy procedures, as it is generally well-tolerated by patients and offers quick recovery times. Conversely, the transjugular biopsy segment, while essential, holds a smaller market share, appealing primarily to patients with specific medical conditions that make other methods less viable. The growth trends in the liver biopsy segment are driven by increasing awareness of liver diseases and the need for accurate diagnosis. The laparoscopic biopsy is emerging as the fastest-growing technique, thanks to advancements in technology and surgical methods that enhance safety and effectiveness. These trends indicate an ongoing evolution in biopsy techniques, with telemedicine and robotic-assisted procedures also gaining traction in the coming years.</p>

    <p>Percutaneous Biopsy (Dominant) vs. Transjugular Biopsy (Emerging)</p>

    <p>Percutaneous biopsy is recognized as the dominant approach in the liver biopsy market, favored for its simplicity and lower risk of complications. It typically involves the insertion of a needle through the skin to obtain liver tissue samples, making it suitable for outpatients. In contrast, transjugular biopsy, while less common, offers advantages for patients with underlying conditions such as coagulopathy or ascites, as it provides access to the liver via the jugular vein. Despite its emerging status, the transjugular approach is gaining prominence, particularly in specialized settings, due to the increased focus on patient safety and precision in liver disease diagnosis.</p>

    By Indication: Nonalcoholic Fatty Liver Disease (Largest) vs. Chronic Hepatitis B or C (Fastest-Growing)

    <p>The liver biopsy market, categorized by indication, reveals a significant distribution in favor of nonalcoholic fatty liver disease (NAFLD), which has emerged as the largest segment due to the rising prevalence of obesity and metabolic disorders. In contrast, chronic hepatitis B and C are witnessing increased attention, promising substantial growth as diagnostic and treatment methods advance. Other segments like autoimmune hepatitis and alcoholic liver disease also contribute to the market dynamics but do not match the scale of NAFLD or the growth rate of hepatitis cases.</p>

    <p>Nonalcoholic Fatty Liver Disease (Dominant) vs. Chronic Hepatitis B or C (Emerging)</p>

    <p>Nonalcoholic fatty liver disease (NAFLD) remains the dominant indication in the liver biopsy market, attributed to its link with widespread lifestyle-related health issues. NAFLD's growing prevalence necessitates effective diagnosis, thus fueling demand for liver biopsies. On the other hand, chronic hepatitis B and C are emerging as fast-growing segments, primarily driven by increased awareness about viral hepatitis and advancements in treatment options. While NAFLD is primarily linked to lifestyle factors, hepatitis B and C cases are driven by infectious pathogens, representing diverse underlying causes for liver damage. Both segments have distinct clinical implications, influencing their management strategies and the overall landscape of liver health care.</p>

    By End User: Hospitals & Clinics (Largest) vs. Tertiary Care Centers (Fastest-Growing)

    <p>The Liver Biopsy Market shows a diverse distribution among its end users, with Hospitals & Clinics leading the way as the dominant segment. They account for a significant portion of the market share due to their extensive resources and increasing patient referrals for liver-related ailments. Tertiary Care Centers, while currently smaller in share, are experiencing rapid growth driven by specialized treatments and advanced technologies attracting more patients requiring liver biopsy procedures.</p>

    <p>Hospitals & Clinics (Dominant) vs. Tertiary Care Centers (Emerging)</p>

    <p>Hospitals & Clinics have solidified their position as the dominant players in the Liver Biopsy Market by providing comprehensive care that includes biopsy procedures among a wide array of hospital services. These facilities are equipped with advanced diagnostic tools and have a steady influx of patients, making them vital in managing liver diseases. In contrast, Tertiary Care Centers are emerging as significant contributors to the market due to their specialized focus and capacity to handle complex cases. Their cutting-edge technologies and expert teams cater to higher-tier patients, allowing for innovative biopsy techniques and treatments, thus driving their growth within this sector.</p>

    Get more detailed insights about Liver Biopsy Market Research Report–Forecast till 2035

    Regional Insights

    Key Companies in the Liver Biopsy Market market include

    Industry Developments

    Future Outlook

    Liver Biopsy Market Future Outlook

    <p>The Liver Biopsy Market is projected to grow at a 7.51% CAGR from 2024 to 2035, driven by advancements in diagnostic technologies and increasing prevalence of liver diseases.</p>

    New opportunities lie in:

    • <p>Development of minimally invasive biopsy devices for outpatient settings.</p>
    • <p>Integration of AI-driven analytics for enhanced diagnostic accuracy.</p>
    • <p>Expansion of telemedicine platforms for remote biopsy consultations.</p>

    <p>By 2035, the Liver Biopsy Market is expected to achieve substantial growth, reflecting evolving healthcare demands.</p>

    Market Segmentation

    Liver Biopsy Market Type Outlook

    • Percutaneous biopsy
    • Transjugular biopsy
    • Laparoscopic biopsy

    Liver Biopsy Market End User Outlook

    • Hospitals & Clinics
    • Tertiary Care Centers
    • Urology Centers
    • Others

    Liver Biopsy Market Indication Outlook

    • Nonalcoholic fatty liver disease
    • Chronic hepatitis B or C
    • Autoimmune hepatitis
    • Alcoholic liver disease
    • Others

    Report Scope

    MARKET SIZE 20240.92(USD Billion)
    MARKET SIZE 20250.9891(USD Billion)
    MARKET SIZE 20352.04(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)7.51% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in minimally invasive techniques enhance patient outcomes in the Liver Biopsy Market.
    Key Market DynamicsTechnological advancements in imaging and needle techniques enhance accuracy and safety in liver biopsy procedures.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    What is the expected growth rate of the global liver biopsy market?

    Liver biopsy market size is projected to expand at 6.92% CAGR from 2024-2032.

    What factors can drive the global liver biopsy market?

    Liver biopsy market is driven by large prevalence of liver diseases and a rise of biopsy tests undertaken for its diagnosis.

    What factors can restrain the global liver biopsy market growth?

    High costs of diagnostic devices can stunt the global liver biopsy market growth.

    Name the key players of the global liver biopsy market?

    Fujifilm Medical Systems, Leica Biosystems, Medtronic, RI.MOS., INRAD Inc., Intact Medical Corp., Cook Medical, Hologic, Inc., Mauna Kea Technologies, Veran medical, Sterylab, Argon Medical Devices, Inc., Becton, Dickinson and Company, C. R. Bard, Inc., Boston Scientific Corporation, and MDxHealth are key players of the global liver biopsy market.

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Type (USD Billion)
      2. | | 4.1.1 Percutaneous biopsy
      3. | | 4.1.2 Transjugular biopsy
      4. | | 4.1.3 Laparoscopic biopsy
      5. | 4.2 Healthcare, BY Indication (USD Billion)
      6. | | 4.2.1 Nonalcoholic fatty liver disease
      7. | | 4.2.2 Chronic hepatitis B or C
      8. | | 4.2.3 Autoimmune hepatitis
      9. | | 4.2.4 Alcoholic liver disease
      10. | | 4.2.5 Others
      11. | 4.3 Healthcare, BY End User (USD Billion)
      12. | | 4.3.1 Hospitals & Clinics
      13. | | 4.3.2 Tertiary Care Centers
      14. | | 4.3.3 Urology Centers
      15. | | 4.3.4 Others
      16. | 4.4 Healthcare, BY Region (USD Billion)
      17. | | 4.4.1 North America
      18. | | | 4.4.1.1 US
      19. | | | 4.4.1.2 Canada
      20. | | 4.4.2 Europe
      21. | | | 4.4.2.1 Germany
      22. | | | 4.4.2.2 UK
      23. | | | 4.4.2.3 France
      24. | | | 4.4.2.4 Russia
      25. | | | 4.4.2.5 Italy
      26. | | | 4.4.2.6 Spain
      27. | | | 4.4.2.7 Rest of Europe
      28. | | 4.4.3 APAC
      29. | | | 4.4.3.1 China
      30. | | | 4.4.3.2 India
      31. | | | 4.4.3.3 Japan
      32. | | | 4.4.3.4 South Korea
      33. | | | 4.4.3.5 Malaysia
      34. | | | 4.4.3.6 Thailand
      35. | | | 4.4.3.7 Indonesia
      36. | | | 4.4.3.8 Rest of APAC
      37. | | 4.4.4 South America
      38. | | | 4.4.4.1 Brazil
      39. | | | 4.4.4.2 Mexico
      40. | | | 4.4.4.3 Argentina
      41. | | | 4.4.4.4 Rest of South America
      42. | | 4.4.5 MEA
      43. | | | 4.4.5.1 GCC Countries
      44. | | | 4.4.5.2 South Africa
      45. | | | 4.4.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 F. Hoffmann-La Roche Ltd (CH)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Abbott Laboratories (US)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Thermo Fisher Scientific Inc. (US)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 Siemens Healthineers (DE)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 Becton, Dickinson and Company (US)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 Medtronic plc (IE)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 Hologic, Inc. (US)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 PerkinElmer, Inc. (US)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | 5.3 Appendix
      65. | | 5.3.1 References
      66. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY TYPE
      4. | 6.4 US MARKET ANALYSIS BY INDICATION
      5. | 6.5 US MARKET ANALYSIS BY END USER
      6. | 6.6 CANADA MARKET ANALYSIS BY TYPE
      7. | 6.7 CANADA MARKET ANALYSIS BY INDICATION
      8. | 6.8 CANADA MARKET ANALYSIS BY END USER
      9. | 6.9 EUROPE MARKET ANALYSIS
      10. | 6.10 GERMANY MARKET ANALYSIS BY TYPE
      11. | 6.11 GERMANY MARKET ANALYSIS BY INDICATION
      12. | 6.12 GERMANY MARKET ANALYSIS BY END USER
      13. | 6.13 UK MARKET ANALYSIS BY TYPE
      14. | 6.14 UK MARKET ANALYSIS BY INDICATION
      15. | 6.15 UK MARKET ANALYSIS BY END USER
      16. | 6.16 FRANCE MARKET ANALYSIS BY TYPE
      17. | 6.17 FRANCE MARKET ANALYSIS BY INDICATION
      18. | 6.18 FRANCE MARKET ANALYSIS BY END USER
      19. | 6.19 RUSSIA MARKET ANALYSIS BY TYPE
      20. | 6.20 RUSSIA MARKET ANALYSIS BY INDICATION
      21. | 6.21 RUSSIA MARKET ANALYSIS BY END USER
      22. | 6.22 ITALY MARKET ANALYSIS BY TYPE
      23. | 6.23 ITALY MARKET ANALYSIS BY INDICATION
      24. | 6.24 ITALY MARKET ANALYSIS BY END USER
      25. | 6.25 SPAIN MARKET ANALYSIS BY TYPE
      26. | 6.26 SPAIN MARKET ANALYSIS BY INDICATION
      27. | 6.27 SPAIN MARKET ANALYSIS BY END USER
      28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
      29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY INDICATION
      30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER
      31. | 6.31 APAC MARKET ANALYSIS
      32. | 6.32 CHINA MARKET ANALYSIS BY TYPE
      33. | 6.33 CHINA MARKET ANALYSIS BY INDICATION
      34. | 6.34 CHINA MARKET ANALYSIS BY END USER
      35. | 6.35 INDIA MARKET ANALYSIS BY TYPE
      36. | 6.36 INDIA MARKET ANALYSIS BY INDICATION
      37. | 6.37 INDIA MARKET ANALYSIS BY END USER
      38. | 6.38 JAPAN MARKET ANALYSIS BY TYPE
      39. | 6.39 JAPAN MARKET ANALYSIS BY INDICATION
      40. | 6.40 JAPAN MARKET ANALYSIS BY END USER
      41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
      42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY INDICATION
      43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER
      44. | 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
      45. | 6.45 MALAYSIA MARKET ANALYSIS BY INDICATION
      46. | 6.46 MALAYSIA MARKET ANALYSIS BY END USER
      47. | 6.47 THAILAND MARKET ANALYSIS BY TYPE
      48. | 6.48 THAILAND MARKET ANALYSIS BY INDICATION
      49. | 6.49 THAILAND MARKET ANALYSIS BY END USER
      50. | 6.50 INDONESIA MARKET ANALYSIS BY TYPE
      51. | 6.51 INDONESIA MARKET ANALYSIS BY INDICATION
      52. | 6.52 INDONESIA MARKET ANALYSIS BY END USER
      53. | 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
      54. | 6.54 REST OF APAC MARKET ANALYSIS BY INDICATION
      55. | 6.55 REST OF APAC MARKET ANALYSIS BY END USER
      56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
      57. | 6.57 BRAZIL MARKET ANALYSIS BY TYPE
      58. | 6.58 BRAZIL MARKET ANALYSIS BY INDICATION
      59. | 6.59 BRAZIL MARKET ANALYSIS BY END USER
      60. | 6.60 MEXICO MARKET ANALYSIS BY TYPE
      61. | 6.61 MEXICO MARKET ANALYSIS BY INDICATION
      62. | 6.62 MEXICO MARKET ANALYSIS BY END USER
      63. | 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
      64. | 6.64 ARGENTINA MARKET ANALYSIS BY INDICATION
      65. | 6.65 ARGENTINA MARKET ANALYSIS BY END USER
      66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
      67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
      68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
      69. | 6.69 MEA MARKET ANALYSIS
      70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
      71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
      72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER
      73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
      74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
      75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER
      76. | 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
      77. | 6.77 REST OF MEA MARKET ANALYSIS BY INDICATION
      78. | 6.78 REST OF MEA MARKET ANALYSIS BY END USER
      79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
      80. | 6.80 RESEARCH PROCESS OF MRFR
      81. | 6.81 DRO ANALYSIS OF HEALTHCARE
      82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
      85. | 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
      86. | 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
      87. | 6.87 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
      88. | 6.88 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
      89. | 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE)
      90. | 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
      91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY INDICATION, 2025-2035 (USD Billion)
      6. | | 7.2.3 BY END USER, 2025-2035 (USD Billion)
      7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      8. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
      9. | | 7.3.2 BY INDICATION, 2025-2035 (USD Billion)
      10. | | 7.3.3 BY END USER, 2025-2035 (USD Billion)
      11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      12. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
      13. | | 7.4.2 BY INDICATION, 2025-2035 (USD Billion)
      14. | | 7.4.3 BY END USER, 2025-2035 (USD Billion)
      15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      16. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
      17. | | 7.5.2 BY INDICATION, 2025-2035 (USD Billion)
      18. | | 7.5.3 BY END USER, 2025-2035 (USD Billion)
      19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      20. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
      21. | | 7.6.2 BY INDICATION, 2025-2035 (USD Billion)
      22. | | 7.6.3 BY END USER, 2025-2035 (USD Billion)
      23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      24. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
      25. | | 7.7.2 BY INDICATION, 2025-2035 (USD Billion)
      26. | | 7.7.3 BY END USER, 2025-2035 (USD Billion)
      27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      28. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
      29. | | 7.8.2 BY INDICATION, 2025-2035 (USD Billion)
      30. | | 7.8.3 BY END USER, 2025-2035 (USD Billion)
      31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      32. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
      33. | | 7.9.2 BY INDICATION, 2025-2035 (USD Billion)
      34. | | 7.9.3 BY END USER, 2025-2035 (USD Billion)
      35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      36. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
      37. | | 7.10.2 BY INDICATION, 2025-2035 (USD Billion)
      38. | | 7.10.3 BY END USER, 2025-2035 (USD Billion)
      39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      40. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
      41. | | 7.11.2 BY INDICATION, 2025-2035 (USD Billion)
      42. | | 7.11.3 BY END USER, 2025-2035 (USD Billion)
      43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      44. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
      45. | | 7.12.2 BY INDICATION, 2025-2035 (USD Billion)
      46. | | 7.12.3 BY END USER, 2025-2035 (USD Billion)
      47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      48. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
      49. | | 7.13.2 BY INDICATION, 2025-2035 (USD Billion)
      50. | | 7.13.3 BY END USER, 2025-2035 (USD Billion)
      51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      52. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
      53. | | 7.14.2 BY INDICATION, 2025-2035 (USD Billion)
      54. | | 7.14.3 BY END USER, 2025-2035 (USD Billion)
      55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      56. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
      57. | | 7.15.2 BY INDICATION, 2025-2035 (USD Billion)
      58. | | 7.15.3 BY END USER, 2025-2035 (USD Billion)
      59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      60. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
      61. | | 7.16.2 BY INDICATION, 2025-2035 (USD Billion)
      62. | | 7.16.3 BY END USER, 2025-2035 (USD Billion)
      63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
      65. | | 7.17.2 BY INDICATION, 2025-2035 (USD Billion)
      66. | | 7.17.3 BY END USER, 2025-2035 (USD Billion)
      67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      68. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
      69. | | 7.18.2 BY INDICATION, 2025-2035 (USD Billion)
      70. | | 7.18.3 BY END USER, 2025-2035 (USD Billion)
      71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      72. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
      73. | | 7.19.2 BY INDICATION, 2025-2035 (USD Billion)
      74. | | 7.19.3 BY END USER, 2025-2035 (USD Billion)
      75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      76. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
      77. | | 7.20.2 BY INDICATION, 2025-2035 (USD Billion)
      78. | | 7.20.3 BY END USER, 2025-2035 (USD Billion)
      79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      80. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
      81. | | 7.21.2 BY INDICATION, 2025-2035 (USD Billion)
      82. | | 7.21.3 BY END USER, 2025-2035 (USD Billion)
      83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      84. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
      85. | | 7.22.2 BY INDICATION, 2025-2035 (USD Billion)
      86. | | 7.22.3 BY END USER, 2025-2035 (USD Billion)
      87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      88. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
      89. | | 7.23.2 BY INDICATION, 2025-2035 (USD Billion)
      90. | | 7.23.3 BY END USER, 2025-2035 (USD Billion)
      91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      92. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
      93. | | 7.24.2 BY INDICATION, 2025-2035 (USD Billion)
      94. | | 7.24.3 BY END USER, 2025-2035 (USD Billion)
      95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      96. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
      97. | | 7.25.2 BY INDICATION, 2025-2035 (USD Billion)
      98. | | 7.25.3 BY END USER, 2025-2035 (USD Billion)
      99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      100. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
      101. | | 7.26.2 BY INDICATION, 2025-2035 (USD Billion)
      102. | | 7.26.3 BY END USER, 2025-2035 (USD Billion)
      103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      104. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
      105. | | 7.27.2 BY INDICATION, 2025-2035 (USD Billion)
      106. | | 7.27.3 BY END USER, 2025-2035 (USD Billion)
      107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      108. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
      109. | | 7.28.2 BY INDICATION, 2025-2035 (USD Billion)
      110. | | 7.28.3 BY END USER, 2025-2035 (USD Billion)
      111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      112. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
      113. | | 7.29.2 BY INDICATION, 2025-2035 (USD Billion)
      114. | | 7.29.3 BY END USER, 2025-2035 (USD Billion)
      115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      116. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
      117. | | 7.30.2 BY INDICATION, 2025-2035 (USD Billion)
      118. | | 7.30.3 BY END USER, 2025-2035 (USD Billion)
      119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      120. | | 7.31.1
      121. | 7.32 ACQUISITION/PARTNERSHIP
      122. | | 7.32.1

    Liver Biopsy Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions